Business UpdateJul 14, 2026, 08:01 AM
Syndax Unveils New Pipeline Assets, R&D Strategy Update
AI Summary
Syndax Pharmaceuticals announced its R&D strategy and new pipeline assets during an R&D Event held on July 14, 2026. The company is expanding its pipeline with SNDX-4321, a novel EGFR inhibitor for NSCLC, and SNDX-62122, a next-generation menin inhibitor for myelofibrosis (MF). Both new candidates are expected to have IND submissions by the end of 2026 or in 2027, with Phase 1 trials commencing in 2027. Additionally, the Phase 2 trial of axatilimab in IPF remains on track for topline data in Q4 2026.
Key Highlights
- SNDX-4321 (EGFR inhibitor for NSCLC) IND submission by end of 2026, Phase 1 trial in 2027.
- SNDX-62122 (menin inhibitor for MF) IND submission and Phase 1 trial in 2027.
- Axatilimab Phase 2 trial in IPF on track for topline data in Q4 2026.
- R&D Event held on July 14, 2026, to highlight new pipeline assets and strategy.
- Company expanding pipeline with internally developed and externally licensed assets.
Price Impact
More from SNDX